Caldic announces the appointment of Charles Davies as CEO Pharma

Press Release

Rotterdam, March 1, 2024: Caldic B.V. announced today the appointment of Charles Davies as CEO Pharma effective March 1, 2024. Charles will succeed John Gorman, who will transition into the role of Strategic Advisor Pharma.

Charles Davies has nearly two decades of experience in the pharmaceutical industry in strategic sourcing and procurement roles. He joins Caldic from Merck & Co., where he was Associate Vice President, Global Sourcing and Procurement.

“With a proven track record in the pharmaceutical industry, Charles is well-positioned to steer Caldic’s pharma business on its global growth journey and deliver customized high-quality solutions to our customers," states Alexander Wessels, Chief Executive Officer, Caldic Group. “We are elated for Charles to join our organization and are confident that his extensive pharma expertise and leadership will bring solid experience to help BrandNu and Caldic further build its capabilities and power to innovate.”

Charles’ extensive career in pharma began with several commercial and business development roles with Dow Chemical and Alcon Laboratories. He worked for ten years at Pfizer in various commercial and procurement leadership roles. At Teva Pharmaceuticals, he was responsible for designing and staffing the Global Procurement organization for Third Party Operations and led the Americas Region Procurement team. He subsequently joinedMerck & Co., in 2017.

“As we welcome Charles, we also want to recognize John’s leadership and commitment throughout his tenure at BrandNu and Caldic. We are grateful to John for his invaluable contributions and look forward to his continued support in the advisory role,” Alexander Wessels adds.